Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last 4,852 GBp
Change Today -47.00 / -0.96%
Volume 1.2M
SHP On Other Exchanges
SHP is not on other exchanges.
As of 11:35 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

shire plc (SHP) Snapshot

4,846 GBp
Previous Close
4,899 GBp
Day High
4,883 GBp
Day Low
4,800 GBp
52 Week High
08/4/15 - 5,870 GBp
52 Week Low
10/16/14 - 3,475 GBp
Market Cap
Average Volume 10 Days
5.24 GBp
Shares Outstanding
15.20 GBp
Dividend Yield
Current Stock Chart for SHIRE PLC (SHP)

shire plc (SHP) Details

Shire plc, a biopharmaceutical company, together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), including VYVANSE/ VENVANSE/ ELVANSE/ TYVENSE/ ELVANS E VUXEN/ADUVANZ; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The company also provides BUCCOLAM for epilepsy treatment; PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist that is used for the treatment of chronic constipation in women. In addition, it offers REPLAGAL for the treatment of Fabry disease; ELAPRASE for the treatment of hunter syndrome; VPRIV for the treatment of type 1 Gaucher disease; and FIRAZYR and CINRYZE C1 esterase inhibitor for the treatment of hereditary angioedema. Further, the company provides FOSRENOL, a phosphate binder for use in end-stage renal disease receiving dialysis; XAGRID that is used for the reduction of elevated platelet counts in at-risk essential thrombocythemia patients; and PLENADREN for the treatment of adrenal insufficiency. Additionally, it licenses its patented antiviral products for human immunodeficiency virus and hepatitis B virus. The company also focuses on the development of resources projects in various therapeutic areas, including rare diseases, neuroscience, ophthalmics, hematology, and gastrointestinal disorders; and early development projects primarily on rare diseases. Shire plc markets its products through wholesalers and pharmacies. The company has research collaboration with ArmaGen Technologies Inc., Santaris Pharma A/S, and Sangamo. Shire plc was founded in 1986 and is based in Dublin, Ireland.

5,016 Employees
Last Reported Date: 02/24/15
Founded in 1986

shire plc (SHP) Top Compensated Officers

Chief Executive Officer, Managing Director an...
Total Annual Compensation: $3.6M
Compensation as of Fiscal Year 2014.

shire plc (SHP) Key Developments

Sangamo BioSciences, Inc. and Shire plc Restructures Collaboration to Accelerate Development of ZFP Therapeutics for the Treatment of Hemophilia and Huntington's Disease

Sangamo BioSciences Inc. announced that the company and its collaborator, Shire plc have agreed to revise their January 2012 collaboration and license agreement to expedite the development of ZFP Therapeutics for hemophilia A and B and Huntington's disease. The decision to restructure reflects a strategic decision by both Shire and Sangamo to focus efforts in areas of current interest and expertise for each company. Under the revised terms of the agreement, Shire will return to Sangamo the exclusive world-wide rights to gene targets for the development, clinical testing and commercialization of ZFP Therapeutics for hemophilia A and B. Shire will retain rights and will continue to develop ZFP Therapeutic clinical leads for Huntington's disease and a ZFP Therapeutic for one additional gene target yet to be named. Shire's rights with respect to other targets contemplated in the original agreement revert to Sangamo. Under the revised agreement, each company is responsible for expenses associated with its own programs and will reimburse the other for any ongoing services provided. Sangamo has granted Shire a right of first negotiation to license the hemophilia A and B programs. No milestone payments will be made on any program and each company will pay certain royalties to the other on commercial sales up to a specified maximum cap. Additional financial details of the agreement will not be disclosed.

Shire plc Appoints Sara Mathew to its Board of Directors as a Non-Executive Director and Member of the Audit, Compliance & Risk Committee of the Board

Shire plc announced the appointment of Sara Mathew to its Board of Directors as a Non-Executive Director. Sara will also be a member of the Audit, Compliance & Risk Committee of the Shire Board. Both appointments will be effective as of September 1, 2015. Sara previously served as Chairman, President and Chief Executive Officer of Dun & Bradstreet Inc., retiring in December 2013.

Shire to Attain Enhanced CINRYZE Manufacturing Flexibility and Capacity

Shire plc announced it has entered into an agreement with Sanquin Blood Supply, providing Shire access to its manufacturing technology and allowing Shire to source additional manufacturers to meet the growing demand for CINRYZE. The specific terms of the agreement are confidential, but involve payments to Sanquin on achievement of certain milestones, including a successful technical transfer to a second source manufacturer. Sanquin will continue to serve as a key partner with Shire to increase global supply of CINRYZE.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SHP:LN 4,852.00 GBp -47.00

SHP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CSL Ltd A$90.18 AUD +0.16
Eisai Co Ltd ¥7,776 JPY -164.00
Mylan NV $48.05 USD +0.63
Perrigo Co PLC $178.80 USD +0.85
View Industry Companies

Industry Analysis


Industry Average

Valuation SHP Industry Range
Price/Earnings 14.4x
Price/Sales 7.1x
Price/Book 4.8x
Price/Cash Flow 13.7x
TEV/Sales 7.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SHIRE PLC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at